Shares of Mangalam Drugs rose 5% today to settle at Rs 35.18 on the NSE.Also read: Ashish Kacholia acquires 2.9% stake in small business Adcounty Media. Stock down 60% from peak
Mangalam Drugs, a Gujarat-based company, started manufacturing active pharmaceutical ingredients (APIs) and intermediates in 1977. It has a multi-product manufacturing facility at two locations and its own research and development laboratory.
Mangalam Drugs’ share price has fallen 69% in the last twelve months. But the stock has seen significant buying over the past month, with shares up nearly 40%.
Despite the late rally, the company’s shares are trading below their 50-day and 200-day simple moving averages (SMAs) of Rs 39.6 and Rs 69.3 respectively, according to Trendlyne data. Also read: Ramkrishna Forgings bulk deal: Morgan Stanley buys shares worth Rs 95 crore
The rally has pushed the counter into strongly overbought territory, with Day’s MFI suggesting a level around 90. A number above 70 is considered overbought, while below 30 is considered oversold.
The company reported a consolidated net loss of Rs 7.4 crore in the quarter ended September 30, 2025, compared to a profit after tax (PAT) of Rs 2.7 crore in the same period a year ago. Total revenue in the quarter under review was Rs 50 crore, down 38% from Rs 80 crore posted by the company in the corresponding quarter of the last fiscal.
(Disclaimer: The recommendations, suggestions, views and opinions expressed by the experts are their own. These do not represent the views of The Economic Times.)
#Mangalam #Drugs #Organics #bulk #deal #Vijay #Kedia #sells #lakh #shares #worth #lakh